Programmed Cell Death 4 (PDCD4)

Programmed Cell Death 4

Programmed Cell Death 4 (PDCD4) is a critical tumor suppressor protein that plays a pivotal role in regulating apoptosis, cell proliferation, and immune responses by modulating gene translation and transcription. PDCD4 primarily exerts its function by binding to eukaryotic initiation factor 4A (eIF4A), inhibiting its helicase activity and preventing the translation of oncogenic mRNAs with complex 5' UTRs, such as cyclin D1 and c-myc^[1]. Additionally, PDCD4 suppresses the transcriptional activity of AP-1 and NF-κB, further contributing to its anti-tumor effects^[2]. Downregulation or loss of PDCD4 has been observed in various cancers, including hepatocellular carcinoma, lung cancer, and breast cancer, where it correlates with tumor progression, metastasis, and poor prognosis^[3]. Due to its tumor-suppressive functions, PDCD4 has emerged as a potential therapeutic target.

References:

[1]. Lankat-Buttgereit B, et al. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biol Cell. 2009 Jun;101(6):309-17. [Content Brief]

[2]. Yang HS, et al. A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A. Mol Cell Biol. 2004 May;24(9):3894-906. [Content Brief]

[3]. Zhong B, et al. Pdcd4 modulates markers of macrophage alternative activation and airway remodeling in antigen-induced pulmonary inflammation. J Leukoc Biol. 2014 Dec;96(6):1065-75. [Content Brief]

Programmed Cell Death 4 (PDCD4) Ligand (1)

Programmed Cell Death 4 (PDCD4) Related Products (3):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-139682A

Dovitinib-RIBOTAC TFA		98.97%
Dovitinib RIBOTAC TFA is an RNA-targeting RIBOTAC degrader that can specifically bind to and degrade pre-miR-21. Dovitinib RIBOTAC TFA can inhibit the metastasis of breast cancer and has anti-tumor activity.

HY-139682

Dovitinib-RIBOTAC		98.93%
Dovitinib RIBOTAC is an RNA-targeting RIBOTAC degrader that can specifically bind to and degrade pre-miR-21. Dovitinib RIBOTAC can inhibit the metastasis of breast cancer and has anti-tumor activity.

HY-P991113

Abazistobart	Ligand
Abazistobart is an immunostimulant and antineoplastic agent targeting the programmed cell death protein 1 (PDCD1). Abazistobart is a chimeric and humanized monoclonal antibody that specifically binds to PDCD1 to block the relevant signaling pathway, thereby activating the immune system and exerting antineoplastic activity. Abazistobart is promising for research of cancers.

Name
Email *

	Sorry, but the email address you supplied was invalid.